Albireo Pharma Sells Bylvay-Associated PRV For $105M

  • Albireo Pharma Inc ALBO has agreed to sell its Priority Review Voucher (PRV) for $105 million. 
  • The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
  • Related Content: Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US.
  • The net sales proceeds expected from the transaction are in addition to the $186.3 million in cash, cash equivalents, and short-term investments Albireo reported as of June 30, 2021.
  • Price Action: ALBO shares are down 0.24% at $29.60 during the market session on the last check Tuesday.

Posted In: BriefsBiotechNewsHealth CareAsset SalesSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.